Nothing said here yet.
to join the conversation.
| ROTHBLATT MARTINE AChairperson & CEO | Sell | 1,678 | $999.9K | Thu, Oct 29 |
| ROTHBLATT MARTINE AChairperson & CEO | Sell | 1,563 | $926.8K | Thu, Oct 29 |
| ROTHBLATT MARTINE AChairperson & CEO | Sell | 1,540 | $914.6K | Thu, Oct 29 |
| ROTHBLATT MARTINE AChairperson & CEO | Sell | 1,355 | $808.7K | Thu, Oct 29 |
| ROTHBLATT MARTINE AChairperson & CEO | Sell | 1,248 | $742.4K | Thu, Oct 29 |
| ROTHBLATT MARTINE AChairperson & CEO | Sell | 1,104 | $653.5K | Thu, Oct 29 |
| ROTHBLATT MARTINE AChairperson & CEO | Sell | 919 | $549.2K | Thu, Oct 29 |
| ROTHBLATT MARTINE AChairperson & CEO | Sell | 53 | $31.3K | Thu, Oct 29 |
| ROTHBLATT MARTINE AChairperson & CEO | Sell | 40 | $24.0K | Thu, Oct 29 |
| ROTHBLATT MARTINE AChairperson & CEO | Sell | 3,086 | $1.8M | Wed, Oct 28 |
| ROTHBLATT MARTINE AChairperson & CEO | Sell | 2,625 | $1.5M | Wed, Oct 28 |
| ROTHBLATT MARTINE AChairperson & CEO | Sell | 1,902 | $1.1M | Wed, Oct 28 |
United Therapeutics (NasdaqGS:UTHR) received FDA clearance to begin clinical trials of Treprostinil-Iloprost SMI for pulmonary arterial hypertension.
United Therapeutics Corporation (NASDAQ:UTHR) has received clearance from the U. S.
United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Shares of United Therapeutics Corporation (UTHR) gain 4,517% since Big Money bought big in 2004.
United Therapeutics (UTHR) faces limited near-term upside for Tyvaso following the Liquidia (LQDA) s
United Therapeutics Corporation (NASDAQ:UTHR) develops treatments for pulmonary arterial hypertension, a rare and dangerous high blood pressure in the lungs, with its Tyvaso franchise at the core.